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In this issue of Archives of Medical Science a Hungarian group reports
on lipid goal achievement in 12,317 high risk patients [1]. This analysis
considers the treatment of dyslipidemia between 2004 and 2008 and also
compares the performance of general practitioners (GPs) and specialists
(9,508 and 2,809 patients, respectively). During this period the percentage
of patients “on target” for low density lipoprotein-cholesterol (LDL-C)
increased from 14% to 32% and 20% to 43% when treated by GPs and
specialists, respectively. In contrast, there was no significant improvement
in high density lipoprotein-cholesterol (HDL-C) or triglyceride (TG) levels.
The conclusion was that “more attention needs to be paid to changing
treatment of patients to achieve target levels”. This includes an increased
use of combination therapy.
The authors [1] attribute the improvement in lipid management between
2004 and 2008 to the application of up-to-date consensus recom  men  -
dations. More specifically, information was provided to physicians via
journals, scientific meetings and country-level coordinators.
We previously conducted 4 pilot best-practice implementation
enhancement programmes aimed at improving risk factor control [2-5].
Physicians from Hospitals or Health Centres recruited patients with
metabolic syndrome (MetS) (628 patients, the SAGE-METS [Standardized
arrangement for a guideline driven treatment of the metabolic syndrome]
study) [2], diabetes mellitus (DM) (578 patients, the INDEED [Initiative for
a new Diabetes therapeutic approach in a Mediterranean country] study)
[3], hypertension (697 patients, the IMPULSION [Implementation of
guidelines for the management of arterial hypertension] study) [4] or
dyslipidemia (1127 patients, the IMPROVE-dyslipidemia [Implementation
of strategy for the management of overt dyslipidemia] study) [5].
Participating physicians attended educational programmes related to
current guidelines for MetS, DM, hypertension, dyslipidemia, overt
cardiovascular disease (CVD), obesity and nutrition [2-5]. The physicians
were motivated to participate as part of their continuing medical education
program. Patients were also motivated by supplying them with a brochure
that included instructions to help them achieve treatment goals.
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The prevalence of dyslipidemia was reduced
from 79 to 24% in the SAGE-METS study [2], from
76 to 12% in the INDEED study [3], from 59.7 to
53.6% in the IMPULSION study [4] and from 100 to
21% in the IMPROVE-dyslipidemia study [5]. The
greatest reduction in LDL-C levels (31.6%) was
observed in patients with dyslipidemia (IMPROVE-
dyslipidemia study) [5]. Triglyceride levels were
significantly reduced in all patient populations 
(p from < 0.002 to < 0.0001 for all comparisons).
High density lipoprotein-cholesterol levels increased
in all studies (p < 0.0001) except for the IMPULSION
study where the rise was not significant. 
All these studies [1-5] highlight the importance
of continuous education of medical practitioners.
Mark  et al. [1] reported a higher percentage 
of patients achieving LDL-C targets when treated
by specialists compared with those followed up by
GPs (43% vs. 32%, respectively; p < 0.0001 by our
calculations). In our studies [2-5] the performance
of specialists and GPs was not compared. 
Mark et al. [1] suggested that the high percentage
of Hungarian patients on a statin may be at least
partly attributed to available generic agents which
are more affordable. The impact of this effect is
likely to increase as more statins (and other lipid-
lowering drugs) become generic. These authors [1]
also specified that the use of combination therapy
(e.g. statin plus ezetimibe) contributed to better
goal achievement. This interpretation is in
agreement with community-based studies that
showed a significantly improved outcome in lipid
targets following the addition of ezetimibe to
a statin [6, 7]. Overall, a meta-analysis (n = 5,039)
concluded that ezetimibe co-administration with
a statin provides significant additional lipid-lowering
effect (a further 23.6% reduction in LDL-C levels; 
p < 0.0001), allowing more patients to achieve 
LDL-C target values [8]. Similar results were
obtained in another recent meta-analysis [9]. Higher
doses of statins represent another therapeutic
option, although this may be associated with an
increased risk of adverse effects [10].
Although reduction of LDL-C remains the primary
goal for lipid-lowering interventions, other targets
(e.g. HDL-C and TG) may also be important [11-13].
In this context, non-HDL-C has also been proposed
as a marker of residual CVD risk [14, 15]. Another
potential therapeutic goal would be apolipoprotein
(apo) A and B levels or their ratio [14, 16-18]. The
advantage when using non-HDL-C, apo A and/or
apo B is that these markers can be measured in the
nonfasting state [14, 16, 17]. However, there is no
definitive evidence showing that raising HDL-C
levels in patients on statins will result in
a significant reduction in vascular events [19, 20].
Similarly, it is not absolutely clear if TG levels
(fasting or non-fasting) are independent predictors
of vascular risk [17, 21-24]; however TG, besides 
LDL-C and C-reactive protein (CRP), seems to be
predictors of cardiovascular events especially in
patients with acute coronary syndromes [12, 25].
The role of “over the counter (OTC)” statins [26,
27] in achieving LDL-C goals is controversial [28-30].
Limitation of OTC statins include the fact that many
countries have not approved this process, the dose
allowed to be prescribed by the pharmacist is low
(e.g. 10 mg simvastatin in the UK) and the cost has
to be paid by the patient [26, 27]. 
Finally, we must deal with all vascular risk factors
(e.g. hypertension, smoking, DM, obesity) and not
just lipids [31, 32]. We should also keep in mind the
increased CVD risk of certain populations (e.g. South
Asians) and the possibility of different therapeutic
targets in those patients [33, 34].
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